Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArthroCare RazorVac System Will Drive 10% Arthroscopy Growth In 2002

This article was originally published in The Gray Sheet

Executive Summary

ArthoCare plans to launch the RazorVac arthroscopy wand for use with its Coblation technology-based radiofrequency arthroscopic surgery system in knee procedures by the first quarter of 2002

You may also be interested in...



ArthroCare

Expanded FDA clearance for the firm's Coblation technology-based radio frequency arthroscopic surgery system includes indications for articular cartilage debridement, ACL/PCL repair, subacromial decompression, meniscectomy and chondroplasty. The system currently is indicated for soft tissue resection, ablation, coagulation and hemostasis in general arthroscopic and orthopedic procedures

Coronavirus Demanding Focus Of US FDA’s Antiviral, Other Divisions

Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.

Akero Heads To Top Of FGF21 Class In NASH; Genfit Says Pandemic Won’t Delay Phase III

Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.

UsernamePublicRestriction

Register

MT015760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel